Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy

被引:17
作者
Tu, Zewei [1 ,2 ,3 ,4 ]
Li, Kuangxun [2 ,3 ,4 ,5 ]
Ji, Qiankun [1 ,2 ,3 ,4 ]
Huang, Yuyang [5 ]
Lv, Shigang [1 ]
Li, Jingying [6 ]
Wu, Lei [1 ,2 ,3 ,4 ]
Huang, Kai [1 ,2 ,3 ,4 ]
Zhu, Xingen [1 ,2 ,3 ,4 ]
机构
[1] Nanchang Univ, Dept Neurosurg, Affiliated Hosp 2, Nanchang 330006, Jiangxi, Peoples R China
[2] Jiangxi Key Lab Neurol Tumors & Cerebrovasc Dis, Nanchang 330006, Jiangxi, Peoples R China
[3] Nanchang Univ, Inst Neurosci, Nanchang 330006, Jiangxi, Peoples R China
[4] JXHC Key Lab Neurol Med, Nanchang 330006, Jiangxi, Peoples R China
[5] Univ Nanchang, Queen Mary Sch, Nanchang 330006, Jiangxi, Peoples R China
[6] Nanchang Univ, Dept Comprehens Intens Care Unit, Affiliated Hosp 2, Nanchang, Peoples R China
基金
中国国家自然科学基金;
关键词
Transporter associated with antigen processing 1 (TAP1); Pan-cancer; Prognostic biomarker; Cancer immunotherapy; Immune Check-point Inhibitor (ICI); DOWN-REGULATION; ANTIGEN; TRANSPORTER; HLA; EXPRESSION; TRANSCRIPTION; MANAGEMENT; CARCINOMA; BLOCKADE; CTLA-4;
D O I
10.1186/s12885-022-10491-w
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundTransporter associated with antigen processing 1 (TAP1) is a molecule involved in processing and presentation of major histocompatibility complex class I restricted antigens, including tumor-associated antigens. TAP1 participates in tumor immunity, and is aberrantly expressed in multiple cancer types;MethodsTranscriptome profiles were obtained from The Cancer Genome Atlas and Genotype-Tissue Expression databases. Genetic alterations, protein distribution, and interaction information for TAP1 were downloaded from cBioPortal, Human Protein Atlas and Compartmentalized Protein-Protein Interaction, respectively. Single-cell analyses of TAP1 across cancers were conducted via the Tumor Immune Single-cell Hub website. Gene set enrichment analysis was employed to investigate TAP1-associated functional mechanisms and processes. Immune cell infiltration was explored using Tumor Immune Estimation Resource 2.0. Pan-cancer correlations between TAP1 expression and immunotherapy biomarkers were explored using the Spearman's correlation test. Associations with immunotherapy responses were also investigated using clinicopathological and prognostic information from cohorts of patients with cancer receiving immune checkpoint inhibitors.ResultsTAP1 expression was elevated in most cancer types and exhibited distinct prognostic value. Immune cells expressed more TAP1 than malignant cells within most tumors. TAP1 expression was significantly correlated with immune-related pathways, T-lymphocyte infiltration, and immunotherapeutic biomarkers. Clinical cohort validation revealed a significant correlation with immune therapeutic effects and verified the prognostic role of TAP1 in immunotherapy. Western blot assay indicated that TAP1 is upregulated in glioblastoma compared with adjacent normal brain tissues.ConclusionTAP1 is a robust tumor prognostic biomarker and a novel predictor of clinical prognosis and immunotherapeutic responses in various cancer types.
引用
收藏
页数:17
相关论文
共 46 条
  • [1] The ABCs of immunology:: Structure and function of TAP, the transporter associated with antigen processing
    Abele, R
    Tampé, R
    [J]. PHYSIOLOGY, 2004, 19 : 216 - 224
  • [2] Immune senescence in non-small cell lung cancer management: therapeutic relevance, biomarkers, and mitigating approaches
    Alexa-Stratulat, Teodora
    Pavel-Tanasa, Mariana
    Cianga, Vlad-Andrei
    Antoniu, Sabina
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (11) : 1197 - 1210
  • [3] interleukin-2: Biology, Design and Application
    Arenas-Ramirez, Natalia
    Woytschak, Janine
    Boyman, Onur
    [J]. TRENDS IN IMMUNOLOGY, 2015, 36 (12) : 763 - 777
  • [4] Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
    Azim, Hamdy A.
    Shohdy, Kyrillus S.
    Elghazawy, Hagar
    Salib, Monica M.
    Almeldin, Doaa
    Kassem, Loay
    [J]. BIOMARKERS, 2022, 27 (08) : 764 - 772
  • [5] HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis
    Bandoh, Nobuyuki
    Ogino, Takeshi
    Katayama, Akihiro
    Takahara, Miki
    Katada, Akihiro
    Hayashi, Tatsuya
    Harabuchi, Yasuaki
    [J]. ONCOLOGY REPORTS, 2010, 23 (04) : 933 - 939
  • [6] Extracellular vesicles in allograft rejection and tolerance
    Benichou, Gilles
    Wang, Mengchuan
    Ahrens, Kaitlan
    Madsen, Joren C.
    [J]. CELLULAR IMMUNOLOGY, 2020, 349
  • [7] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
    Chan, T. A.
    Yarchoan, M.
    Jaffee, E.
    Swanton, C.
    Quezada, S. A.
    Stenzinger, A.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (01) : 44 - 56
  • [8] Immune checkpoint inhibitors: recent progress and potential biomarkers
    Darvin, Pramod
    Toor, Salman M.
    Nair, Varun Sasidharan
    Elkord, Eyad
    [J]. EXPERIMENTAL AND MOLECULAR MEDICINE, 2018, 50 : 1 - 11
  • [9] EPPERSON DE, 1992, J IMMUNOL, V149, P3297
  • [10] ALPHA-INTERFERON-INDUCED TRANSCRIPTION OF HLA AND METALLOTHIONEIN GENES CONTAINING HOMOLOGOUS UPSTREAM SEQUENCES
    FRIEDMAN, RL
    STARK, GR
    [J]. NATURE, 1985, 314 (6012) : 637 - 639